While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...
Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.
Abrysvo® and Arexvy® are Health Canada-approved vaccines for preventing RSV-related lower respiratory tract disease in individuals 60 years of age and older, currently available for high-risk older ...